Number of nuclear medicine examinations unchanged, therapy volumes increasing
The Radiation and Nuclear Safety Authority (STUK) report "Nuclear medicine examinations and treatments in Finland in 2021", published in February 2023, presents the numbers of examinations, treatments and nuclear imaging equipment, and estimates the radiation exposure caused to adults by the examinations.
Inspector Iida Kuurne, the author of the report, says that the study examined the average radiation dose from nuclear medicine examinations carried out 2021 and the total combined radiation doses of Finns.
According to Iida Kuurne, the results show that only a small part of the radiation dose received by Finns is caused by nuclear medicine examinations. An adult participating in a single nuclear medicine examination receives an average dose of 3.4 millisieverts (mSv) from radiopharmaceuticals and a dose of 2.1 mSv from a CT scan, if this is done in addition to the nuclear medicine examination.
When the radiation exposure caused by nuclear medicine examinations is divided among all Finns, the radiation dose is less than 0.05 mSv per citizen per year. The dose has increased slightly in the last ten years. The increase is due to increased CT scans. The average radiation dose received by Finns from all sources combined is 5.9 millisieverts per year. More than five millisieverts come from natural radioactive materials, mainly radon.
The total number of nuclear medicine examinations has remained stable for the last 20 years. The most common nuclear medicine examinations were tumour imaging, examinations of skeletal and soft parts, and examinations of the circulatory system. The most widely used radioactive substances in imaging were technetium-99m, fluorine-18 and iodine-123.
The number of radionuclide therapies has increased every year in the last ten years. Compared to 2009, 58% more treatments were given in 2021. The most common radionuclide therapies are treatment of hyperthyroidism and cancer. The increase in the number of radionuclide therapies is due to new types of treatments that use, for example, Lutetium-177 for the treatment of prostate cancer. The most widely used radioactive substances in radionuclide therapies were iodine-131, lutetium-177 and radium-223.
In radionuclide therapies, as in other radiotherapies, radiation must be used sufficiently to obtain a therapeutic effect. It is international practice not to take radiation exposure into account when calculating the total exposure of citizens.
Keywords
Contacts
Inspector Iida Kuurne, tel. +358 9 759 88 2626
Senior Inspector Sampsa Kaijaluoto, tel. +358 9 759 88 2542
Media contacts, tel. +358 10 850 4761
Images
Links
About Säteilyturvakeskus (STUK)
Säteilyturvakeskus (STUK) on säteily- ja ydinturvallisuutta valvova viranomainen. Tehtävämme on ihmisten, yhteiskunnan, ympäristön ja tulevien sukupolvien suojelu säteilyn haitallisilta vaikutuksilta. STUKissa oli vuoden 2022 alussa yhteensä 336 työntekijää.
Strålsäkerhetscentralen (STUK) är en myndighet som övervakar strål- och kärnsäkerheten. Vårt uppdrag är att skydda människorna, samhället, miljön och de framtida generationerna för strålningens skadliga konsekvenser. I början av 2022 hade STUK sammanlagt 336 anställda.
Radiation and Nuclear Safety Authority (STUK) supervises radiation and nuclear safety in Finland. Our mission is to protect people, society, the environment and future generations from the detrimental effects of radiation. At the beginning of 2022 STUK had 336 employees.
Subscribe to releases from Säteilyturvakeskus (STUK)
Subscribe to all the latest releases from Säteilyturvakeskus (STUK) by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Säteilyturvakeskus (STUK)
TraMeXI: Accuracy for medical X-ray imaging dosimetry27.2.2024 09:45:00 EET | Press release
The Radiation and Nuclear Safety Authority in Finland coordinates the 22NRM01 TraMeXI (Traceability in medical X-ray imaging dosimetry) project supported by the European Union. The aim of the project is to update existing and develop new calibration and measurement methods to ensure the reliability of patients' radiation exposure measurements.
TraMeXI: Noggrannhet i strålningsmätningar inom medicinska röntgenundersökningar27.2.2024 09:45:00 EET | Tiedote
Strålsäkerhetscentralen samordnar projektet 22NRM01 TraMeXI (Traceability in medical X-ray imaging dosimetry) som stöds av Europeiska unionen. Projektet har som mål att uppdatera befintliga och utveckla nya kalibrerings- och mätmetoder som kan användas för att säkerställa tillförlitligheten hos mätningar av patienters strålningsexponering.
TraMeXI: Tarkkuutta lääketieteellisen röntgenkuvantamisen säteilymittauksiin27.2.2024 09:45:00 EET | Tiedote
Säteilyturvakeskus koordinoi Euroopan unionin tukemaa 22NRM01 TraMeXI -nimistä projektia (Traceability in medical X-ray imaging dosimetry). Projektin tavoite on päivittää nykyisiä ja kehittää uusia kalibrointi- ja mittausmenetelmiä, joiden avulla potilaiden säteilyaltistuksen mittausten luotettavuus voidaan varmistaa.
Utbildningen av rescEU-beredskapslagrens experter inleds30.1.2024 08:30:00 EET | Tiedote
Utbildning för experter i användning av utrustning och material i EU:s gemensamma beredskapslager i Finland inleds denna vecka vid Strålsäkerhetscentralen. Efter utbildningen av den första expertgruppen är materialet och experterna redo att gå till uppgiften inom minst två dagar efter att begäran om hjälp har mottagits.
Training of RescEU emergency stockpile experts begins30.1.2024 08:30:00 EET | Press release
The training for experts in the use of the equipment and materials of the EU’s common emergency stockpile facilities located in Finland starts at the Radiation and Nuclear Safety Authority. After the training of the first group, the materials and experts are ready to go within at least two days after the request for help has been received.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom